<DOC>
	<DOCNO>NCT02193490</DOCNO>
	<brief_summary>The purpose study evaluate tolerability preliminary efficacy DNase eye drop patient Sjogren 's Non-Sjogren Dry Eye Disease .</brief_summary>
	<brief_title>DNase Treatment Dry Eyes</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Aged 18 year old . Capable give informed consent provide inform consent . Documented Dry Eye Disease least 6 month . Schirmer I &lt; 10 Corneal/ conjunctival ( Rose Bengal ) stain ≥1 Ocular symptom must consider annoy activity limiting ( OSDI ≥13 ; mild ) . Women must postmenopausal ≥ 1 year , surgically sterilize . If , negative urine pregnancy test require within 14 day receive first dose test medication ( placebo/ study drug ) along definite evidence contraceptive use duration study . Allergic Deoxyribonuclease eye drop similar product , excipients Deoxyribonuclease eye drop 0.1 % . Receiving receive within 30 day experimental systemic medication . Active ocular infection ocular allergy . Any history eyelid surgery ocular surgery within past 3 month . Corneal epithelial defect large 1 mm2 either eye . The use topical cyclosporine corticosteroid within 2 week enrollment Have active drug/alcohol dependence abuse history</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>DNase , Pulmozyme , dry eye disease , treatment</keyword>
</DOC>